Evidence map›Paper›PMID 33706522›Full record

Trial reportBiointerphases2021

Can the biomolecular corona induce an allergic reaction?-A proof-of-concept study.

Anne Muehe, Hossein Nejadnik, Henrik Muehe, Jarrett Rosenberg, Hassan Gharibi, Amir Ata Saei, Shu-Chen Lyu, Kari C Nadeau, Morteza Mahmoudi, Heike E Daldrup-Link

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Biointerphases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Anne MueheDepartment of Radiology, Pediatric Molecular Imaging, Molecular Imaging Program at Stanford, Stanford University, Stanford, California 94305.
Hossein NejadnikDepartment of Radiology, Pediatric Molecular Imaging, Molecular Imaging Program at Stanford, Stanford University, Stanford, California 94305.
Henrik MueheGoogle Inc., Mountain View, California 94043.
Jarrett RosenbergDepartment of Radiology, Pediatric Molecular Imaging, Molecular Imaging Program at Stanford, Stanford University, Stanford, California 94305.
Hassan GharibiDivision of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-17 177 Stockholm, Sweden.
Amir Ata SaeiDivision of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-17 177 Stockholm, Sweden.
Shu-Chen LyuSean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California 94305.
Kari C NadeauSean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California 94305.
Morteza MahmoudiPrecision Health Program and Department of Radiology, Michigan State University, East Lansing, Michigan 48824.ORCID 0000000225759684
Heike E Daldrup-LinkDepartment of Radiology, Pediatric Molecular Imaging, Molecular Imaging Program at Stanford, Stanford University, Stanford, California 94305.ORCID 000000024929819X
Moog (United States) · USGoogle (United States) · US

Funding

Personalized Whole Body Staging for Children with Cancer: A Solution to the Conundrum of Long-Term Side Effects from CT and PET/CT ScansR01HD081123 · NICHD · STANFORD UNIVERSITY · PI DALDRUP-LINK, HEIKE ELIZABETH · 2015 to 2019
$2.5M
NICHD NIH HHS R01 HD081123
6 · The paper itself

Abstract

Ferumoxytol nanoparticles are being used clinically for the treatment of anemia and molecular imaging in patients. It is well documented that while most patients tolerate ferumoxytol well, a small percentage of patients (i.e., 0.01%) develop severe allergic reactions. The purpose of our proof-of-concept study was to determine whether patients with or without hypersensitivity reactions have specific protein corona profiles around ferumoxytol nanoparticles. In a retrospective, institutional review board approved pilot study, we enrolled 13 pediatric patients (5 girls, 8 boys, mean age 16.9 ± 8.2 years) who received a ferumoxytol-enhanced magnetic resonance imaging and who did (group 1, n = 5) or did not (group 2, n = 8) develop an allergic reaction. Blood samples of these patients were incubated with ferumoxytol, and the formation of a hard protein corona around ferumoxytol nanoparticles was measured by dynamic light scattering, zeta potential, and liquid chromatography-mass spectrometry. We also performed in vitro immune response analyses to randomly selected coronas from each group. Our results provide preliminary evidence that ex vivo analysis of the biomolecular corona may provide useful and predictive information on the possibility of severe allergic reactions to ferumoxytol nanoparticles. In the future, patients with predisposition of an allergic reaction to ferumoxytol may be diagnosed based on the proteomic patterns of the corona around ferumoxytol in their blood sample.

Indexed as

Proof of Concept StudyAdolescentAdultBasophilsFemaleFerrosoferric OxideHumansHypersensitivityImmunityImmunoglobulin EImmunologic MemoryMaleProtein CoronaT-LymphocytesYoung AdultFerrosoferric OxideImmunoglobulin EProtein Corona

Identifiers

PMID33706522
PMCPMC7861880
OpenAlexW3127062498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.